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Ion mobility spectrometry (IMS) instrumentation has been identified as a
suitable technology for the detection and reporting of drug product and detergent
residues from pharmaceutical manufacturing equipment. Ion mobility is not a

new technology, but is entering the field of cleaning validation because of
tightened requirements from the US Food and Drug Administration (FDA).
The purpose of this thesis is to outline a practical implementation of the
analytical technique, Ion Mobility Spectrometry in a cleaning validation program.
Ion Mobility Spectrometry (IMS) is fast and specific for the analysis of small
organic molecules and has been gaining popularity in the pharmaceutical
industry. The challenge in the implementation of any new analytical technique in
a pharmaceutical laboratory is establishing suitable methodology and this thesis
will outline the steps taken for developing and validating a method for detection
of the antihistamine drug Loratadine. The author will also provide a detailed
introduction to the requirements of equipment qualification, cleaning validation
and analytical method validation programs in the pharmaceutical industry.
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CHAPTER 1

INTRODUCTION

The US Food and Drug Administration requires that all pharmaceutical

manufacturing facilities maintain a cleaning validation program to demonstrate
the cleanliness of the equipment used to manufacture drug products. The

requirements of the cleaning validation program are outlined in the current Good
Manufacturing Practices (cGMPs). The cGMPs are a compilation of regulations
for the pharmaceutical industry as found in the Code of Federal Regulations

(CFR).3 The pharmaceutical firm is responsible for establishing a program which
is supported with analytical data demonstrating that the equipment is essentially
free of drug substance and detergent residue.

High Pressure Liquid Chromatography (HPLC) is a very common
technique for analysis of small molecules used in the pharmaceutical industry.
Another instrumentation technique gaining popularity in the industry is Ion

Mobility Spectrometry (IMS), which is capable of quantifying many of the same
analytes as HPLC, but in a fraction of the time. Speed of analysis is critical in all
quality control laboratories, but specifically for cleaning validation due to the cost
of leaving manufacturing equipment quarantined awaiting testing. This chapter
will provide a brief introduction to IMS technology and cleaning validation as well

as the equipment qualification requirements for new instrumentation used for
release of drug products or manufacturing equipment.
1.1 Ion Mobility Spectrometry

Ion mobility spectrometers separate ions based upon their mobility

through a gas. The ions generated by the ion source are propelled through a

drift tube by an applied electric field. Unlike mass spectrometry the drift tube in
an IMS contains a neutral carrier gas, such as compressed air, which provides
resistance for the moving ions. By this principle, analytes are separated by their

size and shape, not only by their mass and charge.1 Because separation of
target analytes takes place in the gas phase, there is no need for complicated
mobile phase or diluent preparation in the case of liquid chromatography or the
associated costs of vacuum systems in the case of mass spectrometry.
There are five main stages in the analysis of compounds by ion mobility

spectrometry. The first, sample preparation, involves solubilizing the analyte
and/or applying the analyte directly onto the desorbing surface (i.e. using a
Teflon substrate to swab a surface). Next, the analyte is volatilized to the gas

phase and enters an ionization chamber. Ionization may take place according to
several different mechanisms, dependent upon the ionization source. After
ionization, the ions enter the separation stage, where the charged analytes travel
through a drift tube at atmospheric pressure. There the ions are divided into
packets based on size and shape and reach the Faraday plate for detection at

their respective drift times. The relative amount in each ion packet in arbitrary

digital units (du) is plotted against the drift time for all analytes observed in a
plasmagram as shown in Figure 1.1 in 2-dimensional and 3-dimensional
plasmagrams.

Drift Tlmo{ms)
Dm. -nnw 0.0&-20.10 s Sags: W

10

12

14

Drift Time (ms)

Figure 1.1 3-D and 2-D plasmagrams of loratadine
Ion mobility spectrometry first gained its popularity in the field of narcotics

and explosives detection. 1 Since ion mobility is dependent upon shape and
size, a specific ion's mobility is repeatable and unique. The detection level of
IMS instrumentation is so low that the US armed forces, airport security and law
3

enforcement can use a small handheld device and know immediately whether

trace amounts of narcotics or explosives are present.8 IMS units used for
security purposes come in all different shapes and sizes including whole body
scanners which use a puff of air to dislodge any trace residue from a person's

clothing, hair or skin. These devices use a library of reduced mobility values to

quickly identify compounds without the need for a laboratory and authentic
standards. These scanners do not provide quantification of key analytes, but

they are convenient and relatively inexpensive to use.
Another important sector for IMS instrumentation is the field of

pharmaceutical cleaning validation. 7 IMS instrumentation applied on a
production line can provide a limits-based value for a specific drug within a
moment of sample collection. Similar to narcotics, prescription and over-thecounter pharmaceuticals are volatile and ionizable compounds, easily detectable
by IMS technology.

1.2 Equipment Qualification and Calibration in a cGMP Laboratory

All equipment utilized in an analytical or quality control laboratory for

generation of data to be used for release of drug products or substances must
meet cGMP requirements. The cGMPs are a compilation of regulations made by

the US FDA and included in the code of federal regulations under Title 21. 3 The
cGMP specific to laboratory control of instruments states "The calibration of
instruments, apparatus, gauges, and recording devices at suitable intervals in

accordance with an established written program containing specific directions,
schedules, limits for accuracy and precision and provisions for remedial action in

the event accuracy and/or precision limits are not met."4 The programs
developed across the industry to meet these requirements vary greatly, and
many professional groups within the pharmaceutical industry have developed

suggested guides to harmonize the process. The product of one such group is

an article by Sigvardson et.al5, which highlights the major requirements of an
equipment qualification program and also provides examples of tests that are
generally included for some common types of equipment. Because Ion Mobility
is a relatively new technique to the pharmaceutical industry, many of the testing

parameters referenced in this thesis were provided by the instrument vendor2, or
developed by the Author.

Some pharmaceutical firms may require a Design Qualification (DQ) in
order to purchase the instrument. The DQ will outline what function the

instrument will perform within the firm. 4 Although the DQ is not a cGMP
regulatory requirement, it is a worthwhile process to ensure the targeted
instrument meets the firms needs for the required task. Once the instrument is
purchased, there are three main qualification steps, the instrument qualification

(IQ), operational qualification (OQ) and the performance qualification (PQ, or also
referred to as the performance verification or PV). When a software or computer

system is purchased with the instrument, a computer system validation (CSV) is
also be required.
5

1.3 Pharmaceutical Cleaning Validation

In order to prevent carryover, contamination and adulteration of drug
substances and products between batches, the maintenance of a validated

cleaning program is a critical requirement of the US government's current Good

Manufacturing Practices (cGMPs).3 The FDA requires all firms to have an
established cleaning validation program supported by written cleaning

procedures, protocols and reports to show the robustness of the program.
Although there is no one way to design a validation program, the FDA expects a
pharmaceutical firm to have met a few basic requirements, such as written

procedures (including standard operating procedures or SOPs) detailing the
cleaning method for each potential scenario as well as a general procedure for

validating the cleaning process. 4
A validation protocol and report shall be written for each validation study
and approved by management. Within the validation protocol, a pharmaceutical

firm will document the cleaning method employed for the type of equipment or

equipment chain being qualified, limits for the acceptable detergent and drug
substance residue, the sampling procedures, the analytical methodology which
will be used for testing residues, and finally the sensitivity of the analytical

methodology or limit of detection (LOD). The validation report shall clearly state

results of the executed protocol and the validation status of the cleaning process.

The microbiological burden requirement for a cleaning validation program will not
be discussed in this thesis.4

1.3.1 Establishment of Limits for Drug Substances and Detergents

The acceptable limits for detergent and drug substance shall ensure the
efficacy and safety of the firm's product to prevent cross contamination, and must

considerthe sensitivity of the analytical method. 4 The limit must not only
consider the maximum therapeutic dose of the active ingredient and the toxicity
of a detergent component, but should also take into account any known by
products and reactants. For example, when cleaning acetylsalicylic acid, known
by its common name as Aspirin, with a basic detergent, it is possible that

degradation may occur and the analytical method must also be sensitive to its
known degradent, salicylic acid.

Chemical and detergent limits can be calculated either for an individual

piece of equipment, or for a train of equipment utilized in the manufacturing
process. Since most detergents have many proprietary ingredients, a method
utilizing total organic carbon or conductivity is often employed and a limit such as

10 ppm may be acceptable. 9 Not only is it difficult to develop a method for
unknown ingredients, but it is also unlikely that a highly water-soluble detergent
would leave residue when properly rinsed. In cases where a toxic detergent
component is known or the detergent is not highly water-soluble, a more

stringent limit shall be applied. 4

1.4 Analytical Method Development and Validation

Analytical methods should meet the criteria outlined in the International

Conference on Harmonization (ICH) Guidelines to be considered fully validated
for testing of cleaning validation samples. The degree of validation required is
dependent on whether the method will be used for quantitative or limits-based

determination.6 Limits-based methods are commonly used for cleaning
validation because they provide assurance that residue is below a certain level

without the need for exact known quantities. A quantitative method for reporting
of residue levels has been outlined in this thesis; therefore the analytical method
must be accurate, precise, and linear over the desired range of analysis. The

linear range must span the limit of quantification (LOQ) through the residue limit,
and a low detection level (LOD) must be established. The validation shall also
include a recovery study to show that the swab and solvent combination
effectively remove at least 50% of analyte spiked onto a surface representative of

that used for pharmaceutical manufacturing equipment. Pharmaceutical

equipment surfaces may include a number of materials of construction including
stainless steel, rolled steel, anodized aluminum, polypropylene, high-density
polyethylene and many others.

The most acceptable methods of sampling from equipment surfaces are
direct surface sampling and rinse sampling. In most cases a direct surface

sampling is desired because the method does not rely solely on the solubility of

the analyte, and the limit of detection is typically lower.9 One advantage to rinse
8

sampling is the ability for larger areas to be sampled and for use in difficult to

reach areas such as tubing or pumps.6 Direct surface sampling techniques
typically employ a swab that is free of contaminants, detergents and glue, which
may interfere with the analysis. A swab must also be made of a material that is
resistant to many common solvents such as acetone, 2-propanol, methanol and

acetonitrile. During the method development process, a blank swab sample is
extracted and analyzed to ensure that the extraction technique does not cause
interference of the analyte.

With some IMS instruments, a Teflon substrate or wipe may be used
instead of a swab which can be placed directly onto the desorption chamber,
thus avoiding any extraction and dilution which lowers the detection level of the

method. This type of sampling is ideal for organizations with instrumentation
close to the production floor, further reducing the down time of the equipment

being cleaned. This type of sampling however is still subject to similar method
validation criteria and should be able to remove at least 50% of the residue from

an equipment surface.

1.5 Conclusion

This thesis reports the process and steps taken to fully validate IMS
instrumentation for use in a pharmaceutical laboratory. Additionally, the method

validation process and results are provided for the drug product loratadine.

Finally in the concluding Chapter 5, the Author discusses recommendations for
future method validation of cleaning methods.
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CHAPTER 2

SMITHS DETECTION IONSCAN-LS

2.1 Introduction

Although there are many manufacturers of IMS instrumentation, the
IONSCAN-LS by Smith's detection was selected in part because of its equipment
qualification package and 21 CFR Part 11 compliant software, IM-Station. The
IONSCAL-LS differs from the IONSCAN used by security personnel primarily

because it is equipped with an autosampler and High performance injector (HPI),
in addition to its capability for direct analysis of a Teflon wipe.

2.2 Sample Introduction in the IONSCAN-LS

The IONSCAN-LS autosampler is capable of holding up to 120 vials for
automatic analysis. The autosampler deposits analyte to one of two locations,
(1) the Teflon substrate for direct desorption or (2) to the high performance
injector (HPI) capable of heat and pressure ramping. When using direct
desorption, the autosampler deposits an aliquot of analyte directly onto the
Teflon substrate and the analytes are desorbed into the reaction chamber with
temperatures above the melting point of the analyte. The HPI can operate in
either hot or cold injection mode depending upon the complexity of the matrix

and the tendency of the analyte to degrade with heat. The HPI can also be used
in split mode if the analyte concentration is too high. The split mode is also
12

useful if components are present in the solution that must be removed before or
after desorption of the analyte of the interest. Whether the analyte is desorbed
from the substrate or injected by the HPI, the volatilized analyte enters the

reaction chamberto undergo ionization.1
2.3 Ionization in the IONSCAN-LS

The IONSCAN-LS utilizes a 555 MBq 63Ni radiation source, which emits
low energy p-particles. Atmospheric pressure chemical ionization (APCI) is the

primarily mechanism responsible for the ionization of analytes in the IONSCANLS, and both the positive ion mode and negative ion mode will be discussed in

this chapter. Regardless of the mode selected, the p-particles in the ionization
chamber first collide with nitrogen and oxygen to create the reactant ions in

equations 1 and 2 to support the subsequent steps of the ionization reactions.1

N2 + e"^N+2 + 2e

(Eq 1)

02 + e ^ 0_2

(Eq 2)

2.3.1 Positive Ion Chemistry

Positive ion chemistry is most commonly used for small pharmaceutical
molecules due to their tendency to have functional groups with high proton

affinity, see Figure 2.1 for a list of functional groups according to the their proton
affinity.
13

Amines

Phosphorus Compounds
Sulfoxides
Ketones
Esters

Alkenes
Alcohols
Aromatics

Alkanes

Figure 2.1. List of functional groups from high proton affinity (top) to low

proton affinity (bottom) 1
When undergoing positive ion chemistry, the product ions in Equation 1
interact with the water in the atmosphere to form water clusters according to the

reaction scheme in Equations 3, 4, 5 and 6 as described by Eiceman and

Karpas.2 The IONSCAN-LS utilizes a Drierite cartridge to reduce the
atmospheric moisture concentration to less than 10 ppm water in the ionization
chamber. The degree of proton hydration can vary with the moisture level in the
chamber, so the Drierite serves the critical purpose of maintaining a relatively

constant moisture environment.1 The hydrated proton from Equation 6 now acts
as the primary reactant ion for subsequent reactions.

14

N+2 + 2N2 -> N+4 + N2

(Eq 3)

N+4 + H20 -* 2N2 + H20

(Eq 4)

H20+ + H20 -* H30+ + OH

(Eq 5)

H30+ + H20 + N2 <-> H+(H20)2 + N2

(Eq 6)

The IONSCAN-LS continually emits nicotinamide as an internal calibrant

in the drift gas when operating in positive mode, which also acts as a reactant
ion. The constant presence of nicotinamide in the positive mode means that it is

continually undergoing proton transfer from the hydrated proton and is
responsible for the peak seen in the plasmagrams of Figure 1.1 around 9.5 ms.
After the desorption of the analyte(s), a shift of intensity in the 3-D plasmagram
can be seen from the nicotinamide peak to a new peak representing the analyte
of interest. The reaction of proton transfer to the analyte of interest is illustrated in

equations 7 and 8, where N is nicotinamide and Mis the analyte of interest.1

H+(H20)n + N ^ NH+ + nH20

(Eq 7)

NH++M^MH+ + N

(Eq8)

15

Although the most abundant productwill be the desired MH+ ion, other
reactions do take place in the reaction chamber and an analyst must be

cognizant of the possibility of the confounding product ions in Equations 9 and
10. Cluster ion formation is demonstrated in equation 9, where Q is any other

adduct including water. Dimerization is also possible and may occur when an

excess ofanalyte is present according to equation 10.1

MH+ + nQ ^ QnMH+

(Eq 9)

MH + + M^M2H+

(Eq10)

2.3.2 Negative Ion Chemistry

When the IONSCAN-LS is switched into negative ion mode, nicotinamide

is no longer introduced through the drift gas, and a new reactant compound is
introduced into the reaction chamber. A reactant ion other than the 02"

generated in Equation 2 may be preferential either to reduce the number of
interfering product reactions or to shift the drift time of certain analytes to aid in
separation. In the case of explosives and drug substance detection, CI" is
considered a preferable reactant ion to 02" because the CI" ion provides for

greater sensitivity of compounds with aliphatic or aromatic groups. 2
Hexachloroethane was used as the CI" source in all negative ion mode
experiments in this thesis. The introduction of hexachloroethane into the reaction

16

chamber replaces the product of Equation 2 with that of Equation 11. The

primary chloride reactant ions generated by the IONSCAN-LS is then according

to Equation 12.1

C2CI6 + e"^CI"

(Eq11)

nH20 + CI" -> CI"(H20)n

(Eq 12)

The product ion formation is shown in equations 13 through 16, where M
is the analyte of interest. The most prevalent product ions are expected to be
those generated in Equation 15. As with positive ion mode, the analyst must
always be conscience of the other product ions that may form in the reaction
chamber.

CI"(H20)n + M ^ CI (H20)n + M"

(Eq 13)

CI"(H20)n + M ^ CI (H20)n +(M-H)"

(Eq 14)

CI"(H20)n + M -> M CI"(H20)n

(Eq 15)

M CI"(H20)n + M ^ M2 (H20)n"

(Eq 16)

17

2.4 Separation by Ion Mobility

The product analyte ions enter the drift region via an electronic shutter

gate, which allows a small portion of the population to enter the drift tube every
20-30 milliseconds. Once inside the drift tube, the ions are subject to an applied
electric field, which can be switched from positive to negative polarity as

necessary. While in positive polarity, positively charged ions are accelerated
though the drift tube while neutral molecules and negative ions are exhausted
from the instrument. A drift gas is applied in the opposite direction of ion
movement through the tube, creating a buffering effect for the fast moving ions

as shown in Figure 2.2. With all conditions held constant in the drift tube, ions
are separated according to a characteristic mobility.

Electric field

Ions enter

drift tube
To detectoF

Focusing rings

Figure 2.2 Schematic of a drift region in an ion mobility spectrometer

The mobility constant (K) for an ion packet of similar mass and charge is
proportional to the velocity of the ion through the drift chamber (v) and the
electric field (E) according to Equation 17, where v is in cm/s and E is in cmA/.
18

v

(17)

K= E

The velocity of an ion packet through the drift chamber is dependent upon
such conditions such as temperature and pressure. In order to account for day-

to-day or instrument-to-instrument variability, the reduced ion mobility (K0) for a

given ion packet is normalized where temperature (T) has units of Kelvin and
pressure (P) is expressed as Torr according to Equation 18. The use of an
internal calibrant, allows the IONSCAN-LS to correct for these day-to-day

differences by correcting the ion mobility of the analyte with the known reduced
mobility of the calibrant.

273 P

(18)

*°-*T"760
A number of models have been developed to describe the mobility of ions

through a drift chamber, and the limitations of many are discussed by Eiceman

and Karpas.2 These models aim to explain the relationship between the applied
electric field, drift gas density, an ion's reduced mass and collision cross-section,
as well as the electrostatic interactions taking place within the drift tube.
Lawrence describes the relationship between reduced mobility and the molecular

weight of closely related opiates, suggesting that reduced mobility may be

estimated using the appropriate model. 4 Since many of these factors are held
constant within the IONSCAN-LS, the most critical factor affecting mobility is an
19

ion's collision cross section, used to describe the effective space an ion occupies

while travelling through the drift region. Even ions of the same mass, may exhibit
different mobilities because of their 3-dimensiona! structure and collision cross

section.5 For this reason, Ion mobility spectrometry pairs well with mass
spectrometry in detection and identification of molecules with similar masses.

2.5 Data Generation

The IONSCAN-LS detector uses a simple collector plate to measure the

voltage output from the impacting ions and plot the charge density of each ion
packet in digital units (du) against the drift time in milliseconds (ms) on a 2dimensional plasmagram. Each 2-D plasmagram, or segment is made up of

approximately 15 co-added scans and the shutter gate mechanism allows for the
generation of a new scan every 20 ms. The IONSCAN-LS software stacks the
segments into a 3-D plasmagram, with drift time in the x-dimension and segment
number in the z-dimension. When using direct desorption from the substrate or

the HPI for a hot injection, it can be expected that the analyte will be completely
exhausted in the early segments allowing for a short analysis time. When using
cold HPI injection however, it is possible that analytes will desorb at different
rates, allowing separation of peaks in the x and z-dimension. As part of method
development, the analysis time must be set long enough to ensure complete
desorption from the substrate or the HPI to reduce the likelihood of carryover into

the next injection.1

20

Data generated from the plasmagrams can be reported in two ways by the
IM-Station software; the maximum amplitude (MaxA) represents the peak height

in du of largest detected segments, and the cumulative amplitude (CumA) is the
summation of height in du from all detected segments of the injection. As a part
of method development, both MaxA and CumA values should be collected and

upon finalization of the validation parameters, either CumA or MaxA can be

selected as the best reporting method.1
2.6 References
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CHAPTER 3

IONSCAN-LS EQUIPMENT QUALIFICATION

3.1 Introduction

This chapter will outline some of the general requirements for an

equipment qualification and the steps taken to confirm the suitability of the
IONSCAN-LS for use in cleaning validation. This includes the IQ, OQ and PQ

testing as provided by the vendor and agreed upon by the firm, an annual
calibration program, daily confirmation tests, and the generation of documents
and processes for use of the instrument. All results and information for the
qualification was documented in a formally written report and generated in
accordance with an approved protocol.

The instrument calibration procedure outlined in this chapter was

developed for initial qualification and for the annual calibration to fulfill the
requirements of the equipment qualification lifecycle. The calibration procedure
has two parts, negative ion mode and positive ion mode. Acetaminophen and
dextromethorphan HBr were selected as calibration analytes because they are
actively being controlled in the cleaning validation program and they have shown

suitable responses when analyzed by the IONSCAN-LS. Some of the calibration
procedures and acceptance criteria have been adopted from those provided by
22

the vendor while others were determined based upon repeat analysis and
expected variability.

3.2 Experimental

The IQ was designed by the vendor to ensure the lab has sufficient power
and space to install and operate the instrument efficiently. In addition to the
vendor's requirements, a logbook was created for documenting calibrations,
maintenance activities and other noteworthy information. Because the

IONSCAN-LS houses a regulated radiation source 63Ni, the instrument was
enrolled in a program for testing and monitoring the radiation emitted by the
source.

The instrument OQ and PQ are related in that they ensure the validity of

the data generated by the instrument using a series of tests and measurements.
The vendor's OQ evaluated the instrument's moving parts by measuring the

alignment of the desorber, the autosampler syringe target positions and the
autosampler slide tray positioning. The PQ includes analyzing blanks to
measure the instrument noise and the internal calibrant / reactant responses to

ensure they were within the recommended range. Using trinitrotoluene (TNT)
and diazepam standards, the vendor established limit of detection, linearity,
repeatability and other analytical parameters against agreed upon acceptance
criteria.
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The PQ should also demonstrate that the instrument is capable of

performing the tasks for which it is intended; therefore the Author included the
annual calibration procedure as a part of the PQ documentation for the
IONSCAN-LS. The calibration method utilizes analytes which may also be

analyzed as a part of cleaning validation testing. In this way, the PQ
demonstrates that the instrument is able and ready to perform cleaning validation

testing. An additional document generated during this stage of the qualification is
a method for general use of the instrument and a maintenance procedure
outlining what OQ testing should be repeated in the case of a part change or
repair.

The CSV portion of the qualification program ensures that the data is

generated, stored and processed according to the current guidance's and
requirements. Parts of the CSV include safe guards to ensure no data is lost or

deleted. The computer systems validation ultimately ensures the efficacy of the
data generated by the instrument, but a more detailed explanation will not be
discussed further in this thesis.

3.2.1 Instrument Control Parameters

The instrument conditions and control parameters utilized by the IMStation software to control the IONSCAN-LS, autosampler, and HPI are

discussed in this chapter. All injections utilize the autosampler for delivery to the
HPI in positive ion mode analysis and delivery onto the Teflon substrate for
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negative ion mode analysis. The calibration methods were developed using the
same principles outlined in Chapter 4 with help from the vendor to ensure the
parameters and criteria are a suitable replacement for the calibration program
suggested by Smiths Detection.
3.2.1.1 Negative Ion Mode

In negative ion mode, the control parameters were optimized for analysis
of acetaminophen drug substance. The Teflon substrate was utilized for
negative ion mode, therefore the desorption temperature and analysis time was

adjusted to ensure complete desorption of the analyte from the substrate. The
detection algorithm includes the expected full width at half max based upon the
peak shape consistently generated. The selected parameters and settings are
listed in the following text:

Table 3.1 - Miscellaneous Parameters
Drift heater

111 °C

Inlet heater

205 °C

Desorber heater

200 °C

Calibrant block heater

60 °C

Drift flow

351 cc/ min

Analysis Delay following start of desorption
Scan period
Shutter grid width
Number of co-added scans per segment
Analysis duration
Number of segments per analysis
Sampling period
Number of sample points per scan

0.025 seconds (s)
20 milliseconds (ms)
0.200 ms
15
20 s
67
50 us
379
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Table 3.2 - Detection Algorithm Parameters
Calibrant K<,

1.6520

Calibrant FWHM

300 ms

Calibrant amplitude threshold
Acetaminophen Kq
Acetaminophen FWHM
Acetaminophen amplitude threshold

75 du
1.4220

303 MS
40 du

Table 3.3 - Auto Sampler Parameters
Number of rinses

8

Rinse volume

5.0 mL

Number of sample rinses
Number of sample pumps
Sample fill rate
Sample dispense rate

3
4

40
100

Post fill air volume

1.0 ml

Pre-dispense delay
Post-dispense delay
Dispense to target

0s
6s

Substrate

Minimum substrate cool time

10s

Rinse solvent

Acetone

3.2.1.2 Positive Ion Mode

In positive ion mode, the control parameters were optimized for analysis of
dextromethorphan HBr drug substance. The HPI substrate was utilized for
positive ion mode in hot injection mode. The detection algorithm includes the
expected full width at half max based upon the peak shape consistently

generated. The selected parameters and settings are listed in the following text:
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Table 3.4 - Miscellaneous Parameters
237 °C

Drift heater
Inlet heater

290 °C

Desorber heater

285 °C

Calibrant block heater

70 °C

Drift flow

300 cc / min

Analysis Delay following start of desorption
Scan period
Shutter grid width
Number of co-added scans per segment
Analysis duration
Number of segments per analysis
Sampling period
Number of sample points per scan

0.025 seconds (s)
20 milliseconds (ms)
0.200 ms
8
10s
63

50 ms
379

Table 3.5 - Detection Algorithm
Calibrant K<,

1.8600

Calibrant FWHM

350 ms

Calibrant amplitude threshold
Dextromethorphan HBr Ko
Dextromethorphan HBr FWHM
Dextromethorphan HBr amplitude threshold

500 du
1.1992

413 ms
30 du

Table 3.6 - Auto Sampler Parameters
Number of rinses

5

Rinse volume

5.0 mL

Number of sample rinses
Number of sample pumps
Sample fill rate
Sample dispense rate

0
4

40
100

Post fill air volume

1.0 ml

Pre-dispense delay
Post-dispense delay
Dispense to target

15s
-1 s

Minimum substrate cool time

0s

Rinse solvent

Isopropanol

HPI (Hot)
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3.3 Parameters of Analysis and Acceptance Criteria

The parameters of analysis for the qualification and calibration method
were selected to test the instrument performance for suitability of use and include

functional tests for all segments of the instrument. The acceptance criteria for
the calibration were adapted from vendor recommended criteria to account for

the variability of the instrument and measurable range of the specific analytes.1
Table 3.7 - Negative Ion Mode

Parameter of Calibration

Procedure

Noise Check

Measure the Root Mean

Squared (RMS) amplitude and
peak noise for the last of three
subsequent blank analyses
Calibrant Ion Check

Acceptance Criteria
RMS amplitude < 3 du.
Peak noise < 15 du.

Measure the reduced ion

Kq between 1.6470 and

mobility (Ko), full width at half
max (FWHM) and amplitude of

1.6570

the calibrant ion in a blank

FWHM between 250 and 400
MS

analysis

Max peak Amplitude
> 200 du

Reactant Ion Check

Measure the amplitude of the
reactant ion at the beginning
and end of a blank analysis

Initial reactant amplitude > 600
du

Final reactant amplitude > 200
du

Carryover Check

Measure the amount of carry
over from a concentrated

Limit of Detection Check

Detector Linearity Check

Peak Profile Check

acetaminophen standard (0.78
Mg / mL acetaminophen) in the
last of three acetone injections
Measure the response of three
subsequent injections of dilute
acetaminophen (0.06 Mg / mL)
Measure the response of 7
standards from 0.11 M9 / mL to
0.78 Mg / mL acetaminophen
Measure desorption time at
maximum amplitude and the
total number of segments for
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Average of three carryover
checks have < 2% carryover

Acetaminophen is detected in
all three injections
Correlation Coefficient
>0.98

Desorption time at max
amplitude between 0 and 2.5
seconds

the last of three injections of to
0.56 Mg / mL acetaminophen

Number of detected segments
between 20 and 50

Injector Repeatability Check

Measure the amplitude of six
subsequent injections of to
0.67 Mg / mL acetaminophen

% RSD < 8%

and calculate the relative
standard deviation

Table 3.8 - Positive Ion Mode

Parameter of Calibration

Procedure

Noise Check

Measure the RMS amplitude
and peak noise for the last of
three subsequent blank
analyses

Calibrant Ion Check

Carryover Check

Peak noise < 15 du

Measure the reduced ion

Kq between 1.8550 and

mobility (Ko), full width at half
max (FWHM) and amplitude of

1.8650

the calibrant ion in a blank

HPI Injector Leak Check

Acceptance Criteria
RMS amplitude < 3 du

FWHM between 300 and 480
MS

analysis

Max peak Amplitude > 600 du

Record the actual standby
carrier flow and pressure when

Carrier Flow between 23 and
27 mL/min

set at 25 mL / min

Injector Pressure within 2 psi
of set point

Measure the amount of carry

Average of three carryover
checks have < 2% carryover

over from a concentrated

standard (3.3 Mg / mL
dextromethorphan HBr) in the
last of three isopropanol
Limit of Detection Check

injections
Measure the response of three
subsequent injections of dilute

Dextromethorphan HBr is
detected in all three injections

dextromethorphan HBr (0.4 Mg
/mL)

Detector Linearity Check

Measure the response of 7
standards from 0.8 Mg / mL to
3.3 Mg / mL dextromethorphan

Peak Profile Check

Measure desorption time at
maximum amplitude and the
total number of segments for
the last of three injections of to
2.5 Mg / mL dextromethorphan

Correlation Coefficient > 0.98

HBr

Desorption time at max
amplitude between 0.5 and 3.0
seconds

Number of detected segments
between 5 and 30

HBr

Injector Repeatability Check

Measure the amplitude of six
subsequent injections of to 2.9
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% RSD < 5%

Mg / mL dextromethorphan
HBr

3.4 Preparation and Analysis

The concentrations were selected based upon method development to
determine the range of analysis and the solvent types were selected based on
analyte solubility and to achieve minimal carryover of analyte. The following

concentrations of dextromethorphan HBr were prepared in HPLC grade
isopropanol (Fisher Scientific, Waltham, MA): 0.4, 0.8, 1.2, 1.6, 2.0, 2.5, 2.9 and
3.3 ug / mL dextromethorphan. The following concentrations of Acetaminophen
were prepared in pesticide grade acetone (Fisher Scientific): 0.06, 0.11, 0.22,

0.34, 0.45, 0.56, 0.67 and 0.78 ug / mL acetaminophen.

3.5 Results and Discussion

The results of the PQ demonstrate that the instrument is accurate and

precise over the range of analysis for TNT and Diazepam. Additionally, the tests

in the IQ and OQ show that the functional parts of the instrument are operating
correctly. The initial calibration results demonstrate that the IONSCAN LS is

accurate and precise over the range of analysis for two compounds that are likely
to be analyzed in a cleaning validation program. The results of the calibration

are summarized in tabular form in sections 3.5.1 and 3.5.2. Utilizing quadratic
calibration curves, both acetaminophen and dextromethorphan HBr have
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correlation coefficients greater than 0.99. See Figures 3.1 and 3.2 for plots of the
quadratic fit.
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Figure 3.1 Acetaminophen calibration curve in negative ion mode
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Figure 3.2 Dextromethorphan calibration curve in positive ion mode
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3.5

The desorption profiles of relatively high concentrations of acetaminophen
and dextromethorphan show that the temperature and analysis time is sufficient

to completely desorb the analytes. See Figures 3.3 and 3.4 respectively.
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Figure 3.3 Desorption profile of acetaminophen in positive ion mode
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Figure 3.4 Desorption profile of dextromethorphan in positive ion mode
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Table 3.9 - Negative Ion Mode Results

Parameter of Calibration
Noise Check

Calibrant Ion Check

Procedure

Acceptance Criteria

Measure the Root Mean

RMS amplitude: 0.9 du

Squared (RMS) amplitude and
peak noise for the last of three
subsequent blank analyses

Peak noise: 5.4 du

Measure the reduced ion

Ko: 1.6520

mobility (Ko), full width at half
max (FWHM) and amplitude of

FWHM: 322 us

the calibrant ion in a blank

Max peak Amplitude:

analysis

870.2 du

Reactant Ion Check

Measure the amplitude of the
reactant ion at the beginning
and end of a blank analysis

Initial reactant amplitude:
1889.3 du

Final reactant amplitude:
1914.4 du

Carryover Check

Measure the amount of carry

Average of three carryover

over from a concentrated

checks: 0%

acetaminophen standard (0.78
ug / mL acetaminophen) in the
last of three acetone injections
Limit of Detection Check

Detector Linearity Check

Peak Profile Check

Injector Repeatability Check

Measure the response of three
subsequent injections of dilute
acetaminophen (0.06 ug / mL)
Measure the response of 7
standards from 0.11 ug / mL to

Acetaminophen was detected
in all three injections
Correlation Coefficient: 0.99

0.78 ug / mL acetaminophen
Measure desorption time at
maximum amplitude and the

Desorption time at max
amplitude: 1.2 seconds

total number of segments for
the last of three injections of to
0.56 ug / mL acetaminophen

Number of detected segments:
25 segments

Measure the amplitude of six
subsequent injections of to
0.67 ug / mL acetaminophen
and calculate the relative
standard deviation
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% RSD: 5%

Table 3.10 - Positive Ion Mode Results

Parameter of Calibration

Procedure

Noise Check

Measure the RMS amplitude
and peak noise for the last of
three subsequent blank

Acceptance Criteria
RMS amplitude: 2.1 du
Peak noise: 14.8 du

analyses
Calibrant Ion Check

Measure the reduced ion

Ko: 1.8600

mobility (Ko), full width at half
max (FWHM) and amplitude of

FWHM: 355 us

the calibrant ion in a blank

Max peak Amplitude:

analysis

1859.1 du

HPI Injector Leak Check

Carryover Check

Record the actual standby
carrier flow and pressure when
set at 25 mL / min and 41 psi

Carrier Flow: 25 mL / min

Measure the amount of carry

Average of three carryover

over from a concentrated

checks: 0%

Injector Pressure: 41 psi

standard (3.3 ug / mL
dextromethorphan HBr) in the
last of three isopropanol
Limit of Detection Check

injections
Measure the response of three

subsequent injections of dilute
dextromethorphan HBr (0.4 ug

Dextromethorphan HBr was
detected in all three injections

/mL)

Detector Linearity Check

Measure the response of 7
standards from 0.8 ug / mL to
3.3 ug / mL dextromethorphan

Peak Profile Check

Measure desorption time at
maximum amplitude and the
total number of segments for
the last of three injections of to
2.5 ug / mL dextromethorphan

Injector Repeatability Check

Measure the amplitude of six
subsequent injections of to 2.9
ug / mL dextromethorphan

Correlation Coefficient: 1.00

HBr

Desorption time at max
amplitude: 2.1 seconds
Number of detected segments:
16 segments

HBr

HBr
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% RSD < 3%

3.6 Conclusions

The IQ / OQ / PQ protocol and initial calibration were performed

successfully and a report was written and approved. At this point, the instrument
would be considered suitable for generation of cGMP data like method validation

and cleaning validation data. The calibration procedure is suitable for use during
annual calibration.

3.7 References

1. IONSCAN-LS User Guide 2005, Smiths Detection.
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CHAPTER 4

METHOD DEVELOPMENT AND VALIDATION

4.1 Introduction

The first step in analytical method development is the identification of the

proper technique for quantification of the analyte of interest. HPLC is a very
common technique for analysis of small molecules used in the pharmaceutical

industry because many absorb in the UV range. However, most HPLC methods
require complicated mobile phase preparation or lengthy analysis times due to

the complicated matrix of the drug product and detergents. Although IMS is not
suitable for replacing all HPLC methods, there is a potential benefit of significant
reduction in sample / solution preparation and analysis time for those that are
suitable for IMS.

The main goal in transitioning from HPLC to IMS methodology for the

analysis of cleaning validation samples is the reduction of per sample analysis
time. After a cleaning event, a piece of equipment will remain quarantined until
the results of the swab or rinse sample are received from the laboratory. For
example, the laboratory may receive 18 swab samples from an equipment train

where loratadine and detergent xyz has been used. Until those 18 swab
samples have been tested and the equipment deemed clean by the laboratory
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(i.e. levels of loratadine and detergent xyz below the determined limit), the
equipment train cannot be utilized for further production. The approximate time

required for the analysis of 18 loratadine swab samples by an IMS and HPLC
procedure has been detailed down in Table 4.1. Based upon the estimated times

in Table 4.1, the equipment turn overtime may reduced by as much as 3 hours if
the IMS procedure is utilized. The time savings will vary by product since HPLC

analysis times vary greatly from analyte to analyte. Acetaminophen, for example
may have an analysis time of less than 2 minutes and famotidine may require up
to 10 minutes per sample. When selecting products for the switch from HPLC to
IMS, it should be determined whether the sample analysis time warrants the cost

of method development and validation by IMS. Based upon the information in
Table 4.1 loratadine was identified as a suitable product for transfer from HPLC
to IMS methodology.

Table 4.1 - Example analysis time comparison for HPLC vs IMS of 18 swab
samples submitted for cleaning validation
Procedural Step for
Analysis
Preparation of Mobile
Phase / sample diluent
Instrument Equilibration
Standard preparation
Standards and system
suitability check
analysis time
Sample analysis time

Time required for 18
swab samples by HPLC
Up to 1 hour

Time required for 18
swab samples by IMS
Not Required

Up to 30 minutes

Up to 30 minutes

10 minutes

20 minutes

42 minutes (7 injections
at 6 minutes per
standard)
108 minutes (18
injections at 6 minutes
per sample)

5 minutes (5 injections at
1 minute per standard)

Total Analysis Time

Minimum of 4 hours
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18 minutes (18 injections
at 1 minute per sample)
Minimum of 1 hour

4.2 Experimental

Once loratadine was selected as the analyte, the structure was evaluated

for its ability to volatilize and ionize. As seen in Figure 4.1, loratadine includes
two amine groups and a ketone, all with high proton affinity, making it a good
candidate for positive ion mode analysis. Additionally, the low molecular weight

of 383 g/mol means that it is likely that the desorber will volatilize the molecule.
For initial test injections, several solvents were selected based on the solubility of
loratadine. Because of the sensitivity of the instrument and potential for

carryover, a concentration of less than 10 ug/mL was prepared in each of the
following solvents: acetone, isopropanol, methanol and ethanol. The 10 ug/mL
solutions were injected directly onto the Teflon substrate to be desorbed with a
temperature that is greater than the melting point of loratadine and which can

completely desorb the analyte (280 °C was selected as a default from the
equipment qualification procedure) and an inlet temperature 5-10 °C greater than
the desorber temperature to prevent condensation of the analyte in the inlet.
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Figure 4.1 2D structure of loratadine 4
The IONSCAN-LS User Guide recommends that the selected solvent be

deposited in the middle of the Teflon substrate and allowed to evaporate prior to

desorption of the analyte. These steps ensure even desorption and reduce the
potential for solvent interactions in the reaction chamber. Although acetone and
isopropanol gave suitable result in test injections, isopropanol was selected
because it can be purchased at a lower cost than the pesticide grade acetone.

The drug product was injected early in the development process to

determine if use of the HPI is necessary. The Teflon substrate is the ideal
injection location because it is faster and easier to use than the HPI, but if
analysis of the drug product resulted in carryover of matrix components or

interference with the loratadine peak, the HPI would be necessary. In substrate

test injections of the drug product, the loratadine peak showed good resolution
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from the matrix components and no interference from the detergent, therefore
development work with the HPI was not completed. An example of HPI method

validation for a cleaning method is described in the work of Baert et.al.2 where
the HPI was optimized to achieve good peak shape for the analyte compound
talarozole with a K0 value of 1.072 in the presence of other similarly structured
compounds.

4.2.1 Signal Optimization

The loratadine peak was programed into the software and the peak signal

was optimized from the starting conditions from the calibration procedure for

Dextromethorphan HBr in orderto meet the following criteria:1
1. The peak shape should be sharp with a single maxima in the 2D
plasmagram

a.

The peak must have a width of less than 1.5 times the full width of
the peak at half the max height (FWHM).

2. The peak should have a consistent drift time with a variability of less than
50 us from the programmed mobility.

3. The analyte should be completely desorbed from the substrate within the
analysis time, and will ideally have a desorption profile without excessive
tailing. See Figure 4.2 for example desorption profiles.

a. There must be no carryover from injection to injection.
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b. The start and end of analyte signal must be visible in the desorption
profile.

600

500

II

^^^^

^™»Good Desorption

400

II
•Si 300
"53
X

I 200
100

J
1)

1

^^.

^^»Poor Desorption

/I 1\ ^^N^
1

2

3

4

5

6

•100

Time in seconds

Figure 4.2 Example desorption profile showing good and poor peak shape
In positive ion mode, many of the analytes with similar molecular weights
will respond well to similar instrument conditions. For this reason, the

optimization of control parameters was minimal from those described in section
3.2.1.2 for the calibration procedure. The duration of analysis was increased to
20 seconds in order to prevent carryover from the drug product matrix and
detergent. To allow for evaporation of the isopropanol from the substrate, a post41

dispense delay of 5 seconds was used and proved adequate for all replicates of
the 1 uL injection. The number and volume of sample and rinse injections was
adjusted slightly to further reduce the possibility of carryover and to improve

variability between injections. The optimized control parameters for loratadine
are included in section 4.2.5.

4.2.2 Establishment of Linearity and the Limit of Quantification

As discussed in previous chapters, the IMS technology tends to have a

short linear range. To overcome this obstacle and have a method that covers the

necessary range of analysis for loratadine, a quadratic fit was utilized for the
linearity data. For this reason, at least four of the standard concentrations are
injected during every analysis to provide a calibration curve for the determination
of sample concentration. To ensure the suitability of the quadratic curve during

each analysis, a calibration check near the middle of the range is injected after
every 10 samples and must meet the acceptance criteria: the calibration check
response must be not more than 10% different from the empirical result
calculated by the calibration curve. See figure 4.3 for the quadratic plot of the
linearity standards.
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Figure 4.3 Linearity plot of loratadine using quadratic fit
The target range of analysis for all cleaning methods should cover at least
50 - 150% of the cleaning limit. The limit determined for the loratadine
equipment was 2.0 ug/mL, taking into account the swab area and dilution
volume. Standard concentrations between 0.8 and 3.2 ug/mL loratadine showed

adequate correlation using a quadratic fit to meet the correlation coefficient
acceptance criteria of not less than 0.98. The limit of quantification was

determined to be 0.8 ug/mL loratadine and the 2D plasmagram in figure 4.4
shows that the peak is clearly observable from the baseline.
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Figure 4.4 2D plasmagram of 0.8 ug/mL loratadine
4.2.3 Recovery of Analyte from a Surface

To show recovery from all equipment surface types, the product was

spiked onto small representative surfaces at 100% of the cleaning limit. A swab
was dipped into a solvent and using a systematic technique, the prescribed
surface area was swabbed. (Surface area for swabbing was described as a part

of the cleaning limit determination in Section 1.3.1 p14). The swab solvent was
isopropanol because it is also used as the sample diluent and readily evaporates
from the equipment surface. If recovery studies are not successful with the
sample diluent, other solvents may be explored.

The technique used for swabbing the spiked analyte is critical for the

successful recovery of the analyte and for this reason the technique should be
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standardized between the groups in the lab and those performing the equipment
swabbing in the production facility. The type of swab is also a critical parameter
in recovery studies, and they must be free of all detergents and glues that can
cause interference with the analyte. For all experiments in this thesis, large

Absorbond Sampling Swabs (Part number TX716) from Texwipe were used.

4.2.4 Specificity in the Presence of Drug Product Excipients and Detergent

For the method to be specific for loratadine, the specificity study must

show that the analyte is quantifiable in the presence of the drug product matrix
and all potential detergents that will be used to clean a specific piece of
equipment. Swab samples were prepared with drug product at the cleaning
validation validation limit and the detergent at a level that is likely to be present.
Because the limit of the detergents can be high enough to cause excessive

carryover in the IMS, the visual appearance threshold is used to determine the
concentration of each detergent in the spiked sample. The visual appearance

threshold is the concentration of detergent that is visible on a piece of equipment
in ambient lighting conditions. The rationale for using this threshold is that the
equipment will fail visual inspection if present above this threshold and the swab
will not be submitted to the laboratory for analysis. As seen in Figure 4.4 the
method is specific for loratadine in the presence of three detergents. None of the

detergents used for cleaning the pharmaceutical equipment show significant
response in the 3D plasmagram when spiked at the threshold limit (Loratadine
concentration at 1 ug/mL).
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Sample: 013-[Unknown6-0.00-Combo 1]

File: $T25410-[TM 3334J-00013-0003932-013-[UNKNOWN6-0.00-COMBO 1].POS
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Mode: Positive Ion
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Figure 4.5 3D plasmagram of loratadine in the presence of drug product
excipients and three detergents.

4.2.5 Control Parameters for Analysis of Loratadine

The following control parameters were optimized during method
development and used for all method validation parameters. Based upon

method development, all results were reported using Cumulative Amplitude
measurements.

Table 4.2 - Miscellaneous Parameters
Drift heater

237 °C

Inlet heater

290 °C

Desorber heater

280 °C

Calibrant block heater

70 °C

Drift flow

300 cc / min

Analysis Delay following start of desorption
Scan period

0.025 seconds (s)
20 milliseconds (ms)
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Shutter grid width
Number of co-added scans per segment
Analysis duration
Number of segments per analysis
Sampling period
Number of sample points per scan

0.200 ms
8
20 s

67
50 us
479

Table 4.3 - Detection Algorithm
Calibrant Kq

1.8600

Calibrant FWHM

350 ms

Calibrant amplitude threshold
Loratadine Kq

500 du

1.1992

Loratadine FWHM

533 ms

Loratadine amplitude threshold

20 du

Table 4.4 - Auto Sampler Parameters
Number of rinses

4

Rinse volume

5.0 mL

Number of sample rinses
Number of sample pumps
Sample fill rate
Sample dispense rate

0
4

30
100

Post fill air volume

1.0 mL

Pre-dispense delay
Post-dispense delay
Dispense to target

15s
5s

Minimum substrate cool time

10s

Rinse Solvent

Isopropanol

Substrate

4.3 Method Validation

Utilizing the control parameters in section 4.2.5, the method was validated

according the method validation protocol in section 4.3.1.
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Table 4.5 - Method Validation Protocol

Parameter
Limit of Detection

Procedure

Acceptance Criteria

Inject loratadine at 0.4 Mg / mL

The active peak is visually

(LOD)
Limit of Quantitation

(LOQ)

resolved from the baseline.

Inject loratadine six times at
0.8Mg/mL

% RSD of the six replicates is <
5.0%.

The average percent of theoretical
input of the six injections must be
between 85 % and 115 %.

Linearity

Inject loratadine at the following

The correlation coefficient is >

concentrations: 0.8, 1.2, 1.6,

0.98.

2.0, 2.4, 2.8 and 3.2 Mg / mL
% RSD for the six replicate
injections of each standard
concentration is < 5 %.

Accuracy and
repeatability

Prepare triplicate swab samples
at 50%, 100% and 150% of the
cleaning limit and inject.

Percent recovery of each must be
between 85 % and 115 %.

% RSD of the nine percent
recoveries must not exceed 5 %.
Intermediate Precision

Three analysts prepare three
swab samples at a
concentration of 2 Mg / mL

% RSD of the nine intermediate

precision percent of theoretical
input results is < 5 %.

loratadine on three different

days.

Stability of Solution
(Sample and
Standard)

Prepare three swab samples
and analyze in duplicate every
24 hours against a freshly
prepared standard calibration

Average percent difference
between the initial and various

stability time point solutions is < 2
%.

curve.

Analyze the initial standard
solutions every 24 against a
freshly prepared standard
calibration curve.

Recovery of product
from a surface

Recover finished product
spiked at 100% of the cleaning
limit from representative
equipment surfaces and repeat

% Recovery of the six recovery
samples is > 50 %

six times. Swab each of the six

results is < 25 %.

replicates using a swab dipped
in isopropanol.
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% RSD of six recovery sample

Parameter

Procedure

Acceptance Criteria

Specificity

Prepare and inject product at
100% of the cleaning limit with
each detergent spiked at the
visual appearance threshold.
Prepare a swab blank sample
for comparison purposes.

There should be no significant
interference from the detergent
matrix and the sample preparation

Utilize the results from all

The % difference for each check
standard must be less than 10 %.

System Suitability

parameters of the validation

components.

Correlation Coefficient is > 0.98 for
each calibration curve.

Table 4.6 - Method Validation Results

Parameter

Result

LOD

LOD = 0.4 ug / mL

LOQ

LOQ = 0.8 ug / mL
%RSD6=1.7
Average Empirical Input =101 %

Linearity

Correlation Coefficient- 1.00

Accuracy and
Repeatability

90 %.

Intermediate Precision

% RSD9 = 5 %
% RSD9 = 4 %

Stability of Solution

% of theoretical input = 96, 102, 99, 92, 94, 98, 89, 94,

The standard solution did not meet acceptance criteria.
The standards must be prepared fresh for use.
The swab sample is stable for < 48 hours.

Recovery of product
from a surface

Specificity

% RSD6 = 5 %
% Recovery Avg6 = 81 %

The detergents and product matrix components did not
interfere with the ability to detect and quantify
loratadine swab samples. The empirical result of
loratadine in the combination samples closely matched
the result of the product sample.
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4.4 Conclusions

A quantitative method has been developed and validated to meet ICH

requirements for the following parameters: System Suitability, Limit of Detection
(LOD), Limit of Quantification (LOQ), Linearity, Accuracy (Including recovery from

the equipment surface), Precision, Stability of Solution and Specificity.3 To show
specificity of the method, the analyte was quantitative recovered in the presence
of the drug product matrix (placebo) as well as the detergent used for cleaning
the equipment. The method validation results reported in this thesis demonstrate
that the IONSCAN-LS from Smiths Detection is suitable for the determination of

residual loratadine in swab samples for the purpose of cleaning validation.
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CHAPTER 5

RECOMENDATIONS

Based upon the work completed in this thesis, the Author recommends the

use of the limits-based approach of method validation IMS analysis, because the
required validation parameters is reduced to limit of detection determination,
calculation of recovery from the surface and swab and specificity in the presence
of the placebo or detergent.

Linearity may still be completed, but is not a

requirement and the quadratic fit utilized for loratadine analysis would not be

necessary. By injecting several limit standards during each run, the residue
results can be reported as less than the limit standard with a response

immediately greater than the swab residue response. This approach would
provide a pharmaceutical firm with semi-quantitative swab residue results for

tracking and trending purposes, and would greatly reduce the amount of method
validation work required.
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